Tag Archives: CDTX

Top 5 Value Stocks To Buy Right Now

Russ Kaplan is a money manager and newsletter advisor who focuses on buying value-oriented stocks with a multi-year investment horizon; here’s his top idea for conservative investors over the coming year.

One of the most under appreciated stocks on Wall Street is Apple (APPL). The stock is among the bluest of blue chips.

Apple has a financial rating of A++. On every measure we see — such as price/earning ratio — Apple is undervalued.

With the death of its founder, investors were skeptical about new leadership, but Tim Cook has done an excellent job. He owns over one million shares of the stock.

Apple is constantly developing new products such as the Apple watch and this is not done as a short-term item being rushed onto the market.

Rather, the company takes a long-term perspective and views its product introductions as something that will constantly be improved over the years.

Top 5 Value Stocks To Buy Right Now: Cidara Therapeutics, Inc.(CDTX)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

Top 5 Value Stocks To Buy Right Now: Del Taco Restaurants, Inc.(TACO)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap Mexican restaurant stock Del Taco Restaurants (NASDAQ: TACO) reported fiscal Q3 2017 earnings after the market closed on Thursday with earnings meeting Wall Street expectations plus the Company also revised its guidance for fiscal year 2017 on several key metrics. Total revenuerose 6.3% to$111.0 million driven by a 6.1% increase in Company restaurant sales and a 7.9% increase in franchise revenue. Comparable restaurant sales increased 4.1% system-wide for the fiscal third quarter 2017, resulting in a 10.8% increase on a two-year basis. The Del Taco system has now generated comparable restaurant sales growth for 16 consecutive quarters whileCompany-operated comparable restaurant sales increased 3.7% marking the 21st consecutive quarter of comparable restaurant sales growth. Franchise comparable restaurant sales increased 4.6%. Net income was $5.1 million versus$4.9 million. The CEO commented:


    Cramer’s game plan starts on Monday, with earnings from Del Taco Restaurants (TACO)  . Despite strong same-store sales last quarter, Cramer said he’s expecting a struggle this quarter.

  • [By Lee Jackson]

    Del Taco Restaurants Inc. (NASDAQ: TACO) had a director at the company selling stock last week. The board member shed a total of 831,314 sharesat between $11.40 and $11.84 apiece. The total for the sale was $10 million. The shares ended the weekat $12.36, in a 52-week range of$8.43 to $15.32. The consensus price target is $17.07.

  • [By Jim Robertson]

    On Tuesday, our Under the Radar Moversnewsletter suggested shorting small cap Mexican restaurant stock Del Taco Restaurants (NASDAQ: TACO):

    The downtrend here is clearly well established, But, it cemented itself in place yesterday and today. On Monday the bulls took a shot, pushing and up and off of the 200-day moving average line (green) after finding support there last week. It was a short-lived effort, setting up a drastic change of heart – the people who regretted not getting out a month ago took the small uptick as a second chance to do so. Only this time, the sellers weren’t so shy. TACO broker under the 200-day moving average that had been support just a week earlier, and did so on higher volume. Today’s bearish follow-through is the clincher.

Top 5 Value Stocks To Buy Right Now: Education Realty Trust Inc.(EDR)

Advisors’ Opinion:

  • [By ]

    Education Realty Trust (NYSE: EDR) is a U.S.-based REIT that specializes in owning and managing collegiate housing facilities near universities. With a market cap of $2.8 billion, this is also one of the larger REITs in the United States. EDR made four dividend payments in 2017 totaling $1.54. That gives shares a current yield of 4.3%, more than a 100% premium to the S&P 500’s 2.0%. EDR also has an impressive history of dividend hikes. Since bottoming out at $0.15 in 2008 after the financial crisis, EDR’s dividend payment has jumped 160%.

Top 5 Value Stocks To Buy Right Now: NewStar Financial, Inc.(NEWS)

Advisors’ Opinion:

  • [By Lisa Levin] Related AHT 25 Biggest Mid-Day Gainers For Friday Mid-Day Market Update: Hortonworks Drops Following Weak Results; Freshpet Shares Spike Higher Ashford Hospitality Trust's (AHT) CEO Montgomery Bennet on Q2 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related NEWS Mid-Morning Market Update: Markets Open Higher; Micron To Lower Jobs Mid-Morning Market Update: Markets Open Lower; Broadcom Profit Beats Expectations NewStar Financial's (NEWS) CEO Tim Conway on Q2 2016 Results – Earnings Call Transcript (Seeking Alpha)


Top 5 Value Stocks To Buy Right Now: KeyCorp(KEY)

Advisors’ Opinion:


    But then there was good news from rail transport company CSX (CSX ) , which saw growth in every one of its business lines. Foot Locker (FL) also surprised to the upside, sending shares up a quick 5.3%. Cramer fave and Action Alerts PLUS holding KeyCorp (KEY) also delivered, as did paint maker Sherwin-Williams (SHW) .

  • [By Craig Jones]

    On CNBC's Fast Money Halftime Report, Jon Najarian said he noticed big options volume in the December weekly, 18 strike calls in KeyCorp (NYSE: KEY). He decided to follow the trade and he is going to hold the position for 1 to 2 days.


    On the show’s “Lightning Round” segment, Jim Cramer was bullish on Penn National Gaming (PENN) , KeyCorp (KEY) and TherapeuticsMD (TXMD) .

    Quiet Breakups

  • [By Ben Levisohn]

    We believe investors should continue to own three types of bank stocks: “Return of Capital (RC) Stocks”, “Risk On (RO) Stocks”, and “Multiple Revaluation (MR) Stocks.” RC stocks include M&T Bank (MTB), PNC Financial Services Group (PNC), and SunTrust Banks (STI); RO stocks include Bank of America, Popular (BPOP), Citigroup, JPMorgan, and KeyCorp (KEY); and MR stocks include BB&T (BBT) and PNC Financial Services Group (PNC).

stock recommendation

Gold on Tuesday pushed back above a closely watched, long-term average as investors grew jittery over the impending French presidential election, which could have a pair of antiestablishment candidates facing off for the top job.

June gold
GCM7, +0.96%
gained $7.90, or 0.6% at $1,261.60 an ouncetrading above its 200-day moving average of $1,260.65, which suggests positive momentum building in the yellow metal, if it closes above that level.

stock recommendation: Exactech Inc.(EXAC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

stock recommendation: Cidara Therapeutics, Inc.(CDTX)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

stock recommendation: Datawatch Corporation(DWCH)

Advisors’ Opinion:

  • [By Lisa Levin]

    Datawatch Corporation (NASDAQ: DWCH) shares were also up, gaining 14 percent to $8.10 after the company reported a narrower-than-expected quarterly loss.

stock recommendation: Coach, Inc.(COH)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Ben Levisohn]

    Kate Spade (KATE) caught a bounce on Wednesday when the Wall Street Journalreported that it was actively seeking a buyer. Since then, we’ve learned that the fashion accessories retailer looks set to auction itself off to the highest bidder, with the process potentially beginning next month, with bidders potentially including Coach (COH) and Michael Kors (KORS). In a note today, SunTrust Robinson Humphrey analystPamela Quintiliano and team contend that Kate Spade could fetch as much as $23 a share:

  • [By Jayson Derrick]

    Honorable Mention: Buy-rated Coach Inc (NYSE: COH) with a $49 price target.

    Energy: Halliburton

    Halliburton Company (NYSE: HAL) is a top energy pick for four reasons: 1) the company’s significant leverage to the U.S. onshore market, 2) potential for incremental margin growth, 3) expectations for positive earnings revision and 4) strong balance sheet and a “well respected” management team.

  • [By Ben Levisohn]

    Coach (COH) has risen 1.1% to $37.76 after getting upgraded to Buy from Hold at Evercore ISI.

    Illumina (ILMN) has dropped 2.4% to $156.22 after beating fourth-quarter earnings forecasts but offering first-quarter revenue guidance that fell short of analyst expectations.

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

  • [By Lisa Levin]

    Kate Spade & Co (NASDAQ: KATE) was down, falling around 14 percent to $19.60 after it was reported the company would spend more time to negotiate the Coach Inc (NYSE: COH) offer.

stock recommendation: Vanda Pharmaceuticals Inc.(VNDA)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.

    If you take a look at the chart for Vanda Pharmaceuticals, you’ll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.

    Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.

    Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

top stocks to invest in today

Last October, we issued a trading call to buy Bank of America Corp. (NYSE: BAC) on the drop to $15. This was shortly before the stock rallied to its 52-week high at $25.50, which generated gains of over 61%. Over the past few weeks, we have seen the market give back some of those gains, and we have received messages from readers asking whether it still makes sense to be holding these positions. Categorically, the answer is still a clear “yes,” as the recent declines have been driven by external events that have done almost nothing to alter the fundamental strength of the company. Further, these declines should be viewed as another buying opportunity to gain exposure in a solid company that stands to benefit greatly from the next round of rate hikes that are expected at the Federal Reserve.

top stocks to invest in today: (VIAB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.


    To be sure, there are differences between all these new offerings both on price and channel selection, as well as functions for binge-watching and recording live shows. Google’s YouTube TV won’t include networks owned by Time Warner, Viacom (VIAB) and AMC Networks (AMCX) , but it will offer a DVR service that saves programs for nine months. Play Station Vue offers lots of digital video games, which plays into a large part of Sony’s business.

  • [By Paul Ausick]

    Viacom Inc. (NASDAQ: VIAB) posted a new 52-week low of $27.22 on Tuesday, down about 4.6% from Friday’s closing price of $28.52. The stock’s 52-week high is $46.72. Volume totaled around 5.8 million shares, about 15% above the daily average. The company had no specific news.

  • [By Keith Noonan]

    While 2016 played host to a range of films that underperformed, the biggest flops belonged to Disney (NYSE:DIS), Viacom (NASDAQ:VIA) (NASDAQ:VIAB) and Lions Gate Entertainment (NYSE:LGF.A). Click through the presentation below to get the details on the year’s five biggest film flops and to learn what last year’s movie misfires mean for the companies involved.

top stocks to invest in today: Cidara Therapeutics, Inc.(CDTX)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

top stocks to invest in today: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Chris Lange]

    Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue, compared with the consensus estimates from Thomson Reuters that called for $2.61 in EPS and $7.15 billion in revenue. The same period from last year had $3.32 in EPS and $8.51 billion in revenue.

  • [By Cory Renauer]

    Like most of you, I don’t like to lose money. So you might be wondering why I was so quick to scoop up more shares of Gilead Sciences (NASDAQ:GILD) stock after its latest earnings report. After all, management shared a forecast for 2017 hepatitis C antiviral sales 39% lower than 2016 figures, and that’s at the high end of the provided range.

  • [By Kumar Abhishek]

    The election of Donald Trump as next US President has brought in some good news for Gilead stock. Firstly, the likelihood of action against the company for “price gouging” has declined heavily. Also, Mr. Trump’sproposal to tax repatriation of cash from overseas to U.S. at a concessional rate of 10% instead of 25% can save billions of dollars for the company, if it chooses to repatriate the cash. Gilead has more that $15 billion in overseas cash. Mr. Trump’s proposal could save it around $2.2 billion in taxes. Mr. Trump’s proposal to lower corporate taxes may not have much impact on Gilead as its current tax rate is very low at 17%. (Also Read: The Rally In Gilead Sciences Inc (GILD) Stock Is Just Getting Started)

  • [By Laurie Kulikowski]

    The revenue growth came in higher than the industry average of 13.4%. Since the same quarter one year prior, revenues rose by 37.3%. Growth in the company’s revenue appears to have helped boost the earnings per share.

    The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 68.4% when compared to the same quarter one year prior, rising from $2,731.27 million to $4,600.00 million.


  • [By Kumar Abhishek]

    Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in a massive underperformance. Gilead stock has underperformedeven the iShares NASDAQ Biotech Index ETF (NASDAQ:IBB) which has returned more than 14% during the same period. Gilead stock has been making lower lows and lower highs going into the earnings, indicating a clear downtrend in the stock. The stock hit its 52 week low of $69.78 recently on January 24th, just days ahead of its Q4 earnings result. Gilead Sciences, Incis scheduled to report its Q4 2016 and FY 2016 earnings on 7th of February, after the market close.

top stocks to invest in today: Tata Motors Ltd(TTM)

Advisors’ Opinion:


    I’ve been watching Tata Motors Ltd. (TTM) over the past few years with increasing interest. As India’s largest carmaker, it stands to benefit from the tenfold projected growth in the middle class in both India and China over the next decade.

Cidara Therapeutics: An Attractive Price For A Niche Opportunity With A High Probability Of Success

Cidara Therapeutics is developing a novel echinocandin (CD101) that we believe will compete for first-line treatment of systemic fungal infections in a subset of patients. Current standard of care for patients with invasive candidiasis or candidemia involves daily IV treatment of an echinocandin until they can be safely released with oral azole step-down therapy. Given its once-weekly dosing schedule, it offers the possibility of a quicker path to outpatient treatment over the current once-daily inpatient schedule. Additionally, this approach would be the best available option for patients with azole-resistant infections, contraindications, and those who cant tolerate oral medications. While we see a niche opportunity here as a non-inferior echinocandin option, there would be additional upside if CD101 achieves superiority as it would become the obvious first-line choice for a broader patient population. Additionally, we expect a larger market penetration in the prophylactic setting, where once-weekly CD101 IV could be a more potent outpatient alternative to oral azoles in patients undergoing transplant. While we believe CD101 IV alone more than justifies the current valuation, we expect additional value generation from CD201 and other products from Cloudbreak.

Background and context

Cidara Therapeutics (NASDAQ: CDTX) is an anti-infectives company with both antifungal and antibacterial programs. Their lead asset, CD101, is a novel formulation of a known class of antifungals called echinocandins. Echinocandins target the fungal cell wall and are first-line therapies for most types of invasive candidiasis. CD101 is a structural analog of anidulafungin with some charge and structural modifications that increase its half-life (~133 h in humans), and reduces liver toxicity. CD101 is being evaluated in systemic Candida infections and has received Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations. Current standard of care echinocandins are limited by their dose-limiting toxicities and their daily IV dosing schedule. Additionally, Candida drug resistance is on the rise and so new chemical entities are needed. CD101 would enable initial inpatient treatment followed by subsequent treatments in the outpatient setting. CD101 was also being evaluated as a topical treatment for vulvovaginal candidiasis (VVC). However, this program was discontinued after Cidara announced CD101 topical failed to achieve clinical cure rates comparable to oral fluconazole. Their second program, CD201 is the first product from their Cloudbreak program and will be evaluated in patients with multi-drug resistant (MDR) gram negative infections.


Cidara currently has a market capitalization around $160M and cash and cash equivalents of $84M. With a burn rate of ~$13M/quarter, their cash position should provide runway through 2018. Recently, Cidara announced a $20M private placement from both new and existing institutional investors at a modestly discounted price. Given that this financing was not critically needed and the fair terms of the deal, we see this as a bullish sign.

Clinical management of invasive candidiasis/candidemia and the unmet need

Invasive candidiasis (IC) is a life-threatening Candida infection with a reported mortality rate of 30-40%. The incidence of IC varies substantially by region but has been found to be as low as 3.65 to as high as 26.2 per 100,000 in the US. The most common species of Candida are C. albicans, C. glabrata, C. parapsilosis, C.tropicalis and C. krusei. Up until recently, C. albicans were the most common cause of infection. In the last few years however, there has been a decline in the incidence (70% to 50%) of C. albicans and an increase in isolation of non-albican species most notably C. glabrata, and C. parapsilosis. This phenomenon is of public health interest as these species tend to have higher rates of resistance.

IC is primarily treated using three classes of antifungal agents: polyenes, azoles, and echinocandins. Polyenes, first introduced in the 1950s, are prescribed less often due to severe toxicity and generally low tolerability. Azoles are the most commonly used agents and are largely effective. They are available in both IV and oral formulations, which is advantageous for clinically stable patients who can then be discharged from the hospital and given outpatient oral step-down therapy. Azoles however, have a number of contraindications, and a growing number of Candida species have shown to be resistant to treatment (notably some C. glabrata and all C. krusei isolates). Furthermore, azoles have cross resistance among their class, meaning that once an azole treatment has failed no other azole class can be administered effectively. Echinocandins are a relatively new class of drug but are now widely recommended for the first-line treatment due to favorable toxicity profiles and broad-spectrum activity against Candida (very few cases of resistance have been noted). One main drawback of echinocandins is that they must be administered daily by IV infusion, potentially extending the hospital stay of patients and limiting their use to the hospital setting.

According to the Infectious Disease Society of America (IDSA) guidelines, best treatment practices will start daily IV echinocandin treatment until a point (usually 5-7 days) when the patient can be safely switched to an oral step-down therapy with an azole. Oral step-down enables the remainder of treatment to occur outside the hospital. Estimates from clinical studies suggest the majority (~60%) of patients are unable to switch to oral step-down therapy before finishing 5 full days of IV echinocandin therapy and therefore must stay in the hospital the full 5 days before release. Furthermore, another study assessed the time to azole switch and found nearly 1/3 of patients were unable to safely switch to oral treatment within the first week. 6.7% of patients in this study required IV treatment for 15-28 days. This represents a major economic burden on the healthcare system and provides a strong financial case for an agent that could be used once weekly in the outpatient setting. Additionally, there is further risk when switching from an echinocandin to an azole where resistance is more common and therefore control of the infection might be lost. Accordingly, IDSA guidelines recommend against an oral step-down when the Candida strain is suspected to be resistant to azoles. This is thought to be the case for 2.5-9% of Candida infections. Some species like C. tropicalis show levels of resistance exceeding 20%. With a once weekly echinocandin option, patients with azole-resistant strains could still be released from the hospital and given outpatient treatment.

CD101 topical failure in VVC is a poor predictor of failure in invasive candidiasis

Despite the failure of CD101 topical in VVC, we believe there is still a high likelihood of success for CD101 IV in systemic Candida infections. While CD101 topical achieved very impressive preclinical data in animal models of VVC, these models have many issues and ultimately translate poorly to the clinic. In contrast, there is robust data supporting the translatability of IV antifungals (including several echinocandins) in IC and candidemia. Up until this study, no echinocandin had been evaluated as a topical treatment and therefore posed additional risk.

CD101 IV: Preclinical data

In preclinical models, CD101 has been tested against 713 fungal clinical isolates where it demonstrated activity comparable to other antifungal compounds. In a separate study of 500 recent Candida isolates, CD101 demonstrated fungicidal activity for 95% of evaluable isolates. While CD101 seems to exhibit only comparable activity in in vitro studies, it shows unique drug distribution in animal models of IC that suggest it can better penetrate tissue lesions (See Fig. 2 below from Zhao, et. al). Importantly, CD101 but not micafungin intra-lesion concentrations exceeded the mutant prevention concentration, representing a key area of CD101 differentiation among the class.

Moreover, as shown below, CD101 treatment resulted in significantly less liver burden and 4X more mice with no liver burden when compared with micafungin at 24 hours post-dose (See Fig. 5 below, from Zhao, et. al). Overall, these preclinical data support CD101 non-inferiority and may even predict superiority.

Clinical data

Results from the Phase 1 SAD and MAD studies assessing CD101 safety and tolerability in healthy subjects were disclosed in late 2015 and early 2016, respectively. A table from their publication of these studies is shown below. In both studies, there were no SAEs, including in a high dose cohort of 400mg for three consecutive weeks (the highest dosing schedule used in the current Phase 2 study). Additionally, there were no apparent liver toxicities, an important distinction from existing compounds in this class. Although these studies were done in subjects that were considerably healthier than those with IC or candidemia, other echinocandins, like caspofungin, showed signs of liver toxicity even in healthy volunteers.


PK/PD results from CD101 IV demonstrated an impressive T1/2 of between 125-146 hours and Cmax levels well above the 90% minimum inhibitory concentration (MIC90) values for the majority of pathogenic isolates tested in vitro.

Overall, these clinical data suggest a tolerability profile at par and potentially better than approved echinocandins. Furthermore, these data also suggest CD101 IV should reach therapeutic concentrations sufficient for fungicidal activity against the majority of pathogenic Candida isolates.

Near-term Binary Events

Phase 2 data of CD101 IV in patients with invasive candidiasis or candidemia (STRIVE trial)

The current Phase 2 study in patients with invasive candidiasis or candidemia includes cohorts that receive an initial 400mg dose followed by subsequent 400mg or 200mg doses weekly and will be compared with IV caspofungin followed by oral fluconazole. The primary endpoints include both TEAEs, mycological eradication at day 14, and resolution of systemic signs of infection. According to a recent update from management, the STRIVE trial plus an additional Phase 3 trial with a non-inferiority endpoint (20% margin) will be sufficient for registration. Based on the PK/PD data, coupled with robust activity observed in preclinical models of Candida infection, we see CD101 IV as having a high probability of success in this trial.

CD101 IV opportunity in prophylaxis

Another update from Cidara management was that they have plans to initiate a Phase 3 trial of prophylactic CD101 IV in immunosuppressed patients undergoing transplant or chemotherapy. Management believes a single Phase 3 trial will be sufficient for registration and plan to start the trial in mid 2018. With this potential label expansion, the CD101 opportunity becomes more attractive as it creates another option for patients who have GI absorption issues and cant tolerate oral fluconazole. Given that echinocandin treatment is more potent and less prone to resistance, its use in this context makes sense, except that once-daily IV administration is impractical. However, a once-weekly treatment would allow physicians the option to choose an echinocandin instead of the cocktail of azoles currently used.


The Cloudbreak discovery program has the potential to offer additional opportunity for upside. It takes an immunomodulatory approach to treating infectious disease and given its novelty, may be less prone to mechanisms of resistance. They have established basic proof of concept in an ex vivo model of A. fumigatus, demonstrating enhanced neutrophil recruitment and growth inhibition. Despite promising early results in this model, we were excited to see them shift focus to CD201, a compound targeting MDR gram negative infections. Facilitating neutrophil recruitment to fungal infections makes sense in the context of a healthy immune system, but it makes much less sense under conditions of neutropenia. However, with MDR infections, facilitating a more aggressive immune response could be very valuable, either as a standalone treatment or as a companion with other anti-infectives. Preclinical data thus far suggest CD201 has both inherent antibacterial and immunostimulatory properties. Importantly, they also found isolates were significantly less prone to spontaneous mutagenesis.

Although still in its early days of development, the program should be fully funded through IND with non-dilutive capital from the CARB-X program.


The global market for systemic antifungal therapeutics is estimated to be in excess of $3B. The azoles flucanazole and voricanazole have reached sales of $1B and $700M, respectively, while the most successful class of echinocandin, caspofungin, has peak sales of $600M. While Cidaras CD101 is unlikely to reach blockbuster sales, there is still a considerable market for a once-weekly IV echinocandin that can be administered in the outpatient setting. According to the 2013 AMR hospital guide, the number of weeks of inpatient antifungal treatment per year in the US is 1.8M (from 1.6M patients). It is estimated that ~40% of those patients are discharged on antifungal therapy, with a total average of 3 weeks on therapy (1 in inpatient and 2 in outpatient). There are 640K eligible patients in outpatient x 2 weeks of treatment = 1.28M total weeks of outpatient treatment. Using a treatment cost of $2,500/week the total inpatient and outpatient opportunities are ~$4.5B and $3.2B, respectively. According to management, there is an estimated 213K weeks of prophylaxis treatment per year in the US, which comes to a total $532M opportunity. In a downside scenario, CD101 IV is non-inferior to standard of care, hits the market in 2Q21, and penetrates 0% of inpatient, 2% of outpatient, and 5% of the prophylaxis markets at peak, totaling sales to $90M ($0M + $64M + $26M). In a base case, CD101 IV is non-inferior, hits the market in 2Q21, and penetrates 0% of inpatient, 5% of outpatient, and 10% of the prophylaxis markets at peak, totaling sales to $213M ($0M + $160M + $53M). In an upside scenario, CD101 IV is superior to standard of care, hits the market in 2Q21, and penetrates 5% of inpatient, 10% of outpatient, and 20% of the prophylaxis markets at peak, totaling sales to $651M ($225M + $320M + $106M). Considering the rates of azole resistance and oral intolerance in these patient populations and the convenience and cost savings of once-weekly treatment in the outpatient and prophylaxis settings, these scenarios suggest there is an attractive opportunity here that alone more than justifies the current valuation.


The main commercial competitors to CD101 IV are the approved antifungals which include polyenes, azoles, and other echinocandins. As these compounds become generic (some as soon as 2018), there will be additional pricing pressure for newly approved products. Regardless, CD101 can have attractive competitive positioning for a number of reasons that may still justify favorable pricing:

1.) As a once a week therapy, there is potential for improved compliance when compared to daily IV doses or oral azoles in the outpatient setting

2.) Doctors can continue echinocandin regimens following discharge rather than switching to a different antifungal class like azoles

3.) Issues with azole treatment due to resistant Candida strains or contraindications

One competitor, SCY-078, being developed by Scynexis (NASDAQ: SCYX) is currently in Phase 2 clinical trials. SCY-078 is an orally available echinocandin that could be administered following discharge from the hospital. This potential treatment is in direct competition with CD101. However, there are reasons to believe both drugs could have separate niches in the space given the limits of oral therapies in patients with GI issues (intra-abdominal candidiasis for example) and compliance concerns with sicker, higher risk patients.

Additional competitors include F2G, a UK biotech in the discovery stage, Amplyx, a Series C funded San Diego company starting Phase 2 development in 2018, and Matinas Biopharma (NYSE: MTNB), a company developing an orally available Amphotericin B as a prophylactic in acute lymphoblastic leukemia.

Risks CD101 may prove inferior to daily IV echinocandins followed by oral azole step-down.While we see this as unlikely, CD101 topical did fail to achieve non-inferiority when compared to oral fluconazole. CD101 may prove more toxic in patients with IC or candidemia.Even though CD101 appeared tolerable in healthy volunteers, it remains to be seen how it is tolerated in this sicker patient population. Physicians may be less likely to use a once-weekly IV echinocandin over daily IV treatment. Some ICU doctors we spoke to suggested they liked the dosing flexibility offered from once-daily dosing. These doctors also saw less value in the potential for early discharge to outpatient care as the majority of their patients are very sick. Summary

Overall, given the rise of azole-resistance, and the percentage of patients who cant tolerate oral medication, we see a niche opportunity for CD101 IV in IC, Candidemia and in transplant prophylaxis. With an attractive enterprise value, a reasonable balance sheet, and additional value drivers from their Cloudbreak program, we believe Cidara offers a favorable risk/reward scenario.

Disclosure: I am/we are long CDTX.

Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

About this article:ExpandTagged: Investing Ideas, Long Ideas, Healthcare, BiotechnologyWant to share your opinion on this article? Add a comment.Disagree with this article? Submit your own.To report a factual error in this article, click here

top penny stocks

A million dollars is a lot of money, isn’t it? Not when you’re looking to finance your entire retirement. If you’ve got $1 million tucked away in your retirement savings by the time you’re ready to retire, you won’t starve, but you may not be able to live out your dreams either.

Blame inflation

“Millionaire” has been shorthand for “really, really rich” for a long time. Unfortunately, $1 million doesn’t buy as much as it did when the term millionaire was first coined. You can blame it oninflation, which is the force that causes the dollar to be worth a little less each year.

Inflation varies from year to year, sometimes radically, but over the long haul, it’s averaged about 3% in the U.S. That means that $1 million will buy 3% less stuff, on average, for each year that passes.

top penny stocks: RELM Wireless Corporation(RWC)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested shorting small cap wireless communications manufacturer RELM Wireless Corporation (NYSEMKT: RWC):

top penny stocks: Energy Transfer Equity, L.P.(ETE)

Advisors’ Opinion:

  • [By Charles Sizemore]

     Charles Sizemore is a prolific financial writer, longtime prizedInvestorPlace contributor, and chief investment officer of Sizemore Capital Management. He’s also a two-time winner of our Best Stockscompetition, so he knows how to pick ‘em.

    Never one to choose a straightforward company, Charles went withEnergy Transfer Equity (ETE) for the Best Stocks for 2016 contest. ETE is a complicated beast, a master limited partnership that’s made up of six other energy companies.

    Perhaps the simplest way to think of ETE is as a company with diversified exposure to energy pipelines, which essentially collect tolls as their corporate users send oil and natural gas all across the country.

    Energy Transfer is thick on the income front, with a dividend yield sitting at 8.7% currently.

top penny stocks: Southwestern Energy Company(SWN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Southwestern Energy Co. (NYSE: SWN) is the only stock in this group to get a rating boost. The Jefferies analysts lifted the rating from Underperform to Hold. The 12-month price target was unchanged at $8. The 2017 EPS estimate was lowered from $0.81 to $0.52, and the 2018 estimate was lowered from $0.99 to $0.94. Shares closed Friday at $7.71, in a 52-week range of $6.62 to $15.59, and the consensus price target on the stock is $12.59.

  • [By Teresa Rivas]

    Southwestern Energy (SWN) slid to the bottom of the S&P 500 on Friday, on the heels of its fourth-quarter earnings.

    Southwestern dropped $1, or 12%, to $7.35, while the S&P 500 rose3.53 points, or 0.15%,to 2367.34.

    Southwestern said it earned 8 cents a share, a nickel below the 13 cents analysts were expecting. Revenue slid 0.4% year over year to $684 million, edging past the$683 millionconsensus.

    In addition, Southwestern saidestimated proved natural gas and oil reserves declinedby 15.5%, to approximately5,253 Bcfe at the end of 2016,compared to 6,215 Bcfeat the end of 2015.

    Raymond James’s John Freeman reiterated a Market Perform rating on the stock:

    he 2017 production guidance range of 890-910 Bcfe compares to RJ/Street at 892/893 Bcfe, respectively. Capex guidance of $1.175-1.275 billion was 18% above Street at $1.04 and 13% above RJ $1.08 billion. The production growth implies the company is taking the middle road of their previous growth scenario whereby $1.25 billion/yr of capex thru 2018 translates to an 8-12% CAGR. However, in 2017, the guidance range implies 2-4% growth y/y. Exit-to-exit, SWN is expecting 20% growth vs the Street at 14%.

    Southwestern shares are down more than 32% since the start of the year.

  • [By Matthew DiLallo]

    Natural gas had been under pressure all year, especially after this past February was the warmest since 1954. By mid-March, gas had lost a quarter of its value because of an oversupplied market. However, it awoke from that slumber toward the end of March thanks in part to the triumphant return of winter, which pounded parts of the nation with a major late-season snowstorm. That storm drove up demand for gas, sending the stocks of several gas producers soaring late last month, including Rice Energy and larger rivalsChesapeake Energy (NYSE:CHK) and Southwestern Energy (NYSE:SWN), which both rose more than 5%.

  • [By Ben Levisohn]

    Southwestern Energy (SWN) soared to the top of the S&P 500 today after the price of natural gas soared the most since 2015 today.

    Getty Images

    Southwestern Energygained 5.8% to $10.98 today, while the S&P 500 declined 0.3% to 2,265.18. Front Month Nymex natural gas futures contracts for January delivery jumped 8.6% to $3.5420 per million btu.

    Southwestern Energy’s market capitalization rose to $5.4 billion today from $5.1 billion yesterday. It reported a net loss of $4.6 billion on sales of $2.9 billion in 2015.

  • [By Ben Levisohn]

    Southwestern Energy (SWN) soared to the top of the S&P 500 today as concerns about a cold spell and a report that showed lower natural gas supply sent natural gas prices higher

    Agence France-Presse/Getty Images

    Shares of Southwestern Energy climbed 6.9% to $12.13 today, while the S&P 500 fell 0.4% to 2,191.08.

    Desjardins Capital Markets’ Kristopher Zack and team explain that the “cold weather forecast [is] lighting a fire under NYMEX.” They explain:

    Although oil prices have dominated the headlines following yesterdays OPEC cut, it has also been a fairly supportive week for natural gas producers, with winter NYMEX strip now approaching the US$3.50/mmbtu level, a far cry from last winters experience. La Ni帽a conditions have also been supportive, and we note that next Thursday morning the US Climate Prediction Center will provide its monthly update on the progress of conditions in the El Ni帽o region, which could be a good leading indicator of future weather patterns entering the heart of the winter season from mid-December through early March…

    Temperatures expected to track near normalized levels over next two weeks, which is significantly colder than last winter’s levels. The weather forecast remains fairly constructive for December heating demand, with Heating Degree Days (HDDs) tracking very close to normalized levels through mid-month and particularly cold temperatures expected in the western US.

    Southwestern Energy’s market capitalization rose to $6 billion from $5.6 billion yesterday. It reported a net loss of $4.6 billion on sales of $2.9 billion in 2015.

  • [By Ben Levisohn]

    Southwestern Energy (SWN) soared to the top of the S&P 500 today after Citigroup upgraded the stock to Buy from Neutral today.

    S. MARTIN/AFP/Getty Images

    Southwestern Energygained 5.9% to $7.81 today, while the S&P 500 rose 0.8% to 2,385.26.

    According to TheFlyOnTheWall.com, Citigroup analyst Robert Morris noted that Southwestern’s stock had dropped 50% since September. He did, however, cut his price target to $10 from $14.

    Southwestern Energy’s market capitalization rose to $3.9 billion billion today from $3.7 billion yesterday. It reported a net loss of $2.6 billion on sales of $2.4 billion in 2016.

top penny stocks: Cidara Therapeutics, Inc.(CDTX)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

top penny stocks: Monsanto Company(MON)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    BeforeBayer(NASDAQOTH: BAYRY)arrived onto the scene, I viewedMonsanto(NYSE: MON)as an intriguing growth stock. It has a rich history of delivering value to shareholders and continues to hold a dominant technological edge over key competitors in crop protection products, seeds, and traits. While little has changed its promising pipeline and portfolio, the pending acquisition throws a wrench in anyone’s plans to start or add to a position. Uncertainty stemming from the merger provides several terrible reasons to buy Monsanto at this time.

  • [By Chris Lange]

    Monsanto Co.’s (NYSE: MON) latest quarterly earnings report is expected on Wednesday. The consensus analyst estimates are $1.77 in earnings per share (EPS) and $4.17 billion in revenue. Shares closed trading most recently at $117.02, in a 52-week range of $97.35 to $118.15. The consensus price target is $122.66.

  • [By Shanthi Rexaline]

    Agri-Input Companies — Seeds/ Fertilizers/Pesticides Manufacturers

    Monsanto Company (NYSE: MON): +68.82 percent since 2011. Syngenta AG (ADR) (NYSE: SYT): +56.26 percent since 2011. Mosaic Co (NYSE: MOS): -63.1 percent since 2011. Potash Corporation of Saskatchewan (USA) (NYSE: POT): -67.8 percent since 2011. CF Industries Holdings, Inc. (NYSE: CF): +5.04 percent since 2011. Agrium Inc. (USA) (NYSE: AGU): +1.10 percent since 2011.

    Agri-Finance Companies

nyse stocks

Clues point to a link between a hacking group connected to North Koreaand the ransomware attacks that have crippled computer systems worldwide, according to two cyber-security firms.

Experts at the global cyber-security firm Symantec found that earlier versions of the ransomware known as WannaCry were found on computers that also bore evidence of the cyber tools used against Sony Pictures Entertainment, as well as banks in Poland and Bangladesh’s central bank attacks that all were linked to North Korea.

Also, a researcher at Googlesingled out an identical code used both in the ransomwareand used by the Lazarus Group, a team of hackers tied to North Korea, noted Symantec.

In ablog post, Moscow-based Kaspersky Lab showed screens of thecode, first identified in atweet by Google researcher Neel Mehta, who pointed to the similarity between a WannaCry sample from February 2017 and a sample from Lazarus from February 2015.

nyse stocks: Affimed N.V.(AFMD)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Affimed NV (NASDAQ: AFMD) were down around 21 percent to $1.70. Affimed priced its public offering of 10,000,000 of its common shares at $1.80 per common share.

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma

nyse stocks: Silver Bay Realty Trust Corp.(SBY)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Silver Bay Realty Trust Corp (NYSE: SBY) got a boost, shooting up 18 percent to $21.47. Tricon Capital Group Inc. announced plans to buy Silver Bay Realty Trust for $21.50 per share.

  • [By Mark Holder]

    Instead of competing in one-off auctions, the traditional method of acquiring homes and the one preferred by Silver Bay Realty Trust (NYSE: SBY  ) (NYSE: SBY  ) (NYSE: SBY  ) and American Homes 4 Rent (NYSE: AMH  ) (NYSE: AMH  ) (NYSE: AMH  ) , the company is obtaining non-performing loans in pools that include thousands of loans. The ultimate outcome of these different models is unknown, but the market hasso far supported Altisource Residential.

nyse stocks: SBA Communications Corporation(SBAC)

Advisors’ Opinion:

  • [By Paul R. La Monica]

    And the infrastructure fund has stakes in cell phone tower owners Crown Castle (CCI) and SBA Communications (SBAC), as well as giant British gas and electric utility National Grid (NGG).

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Jon Najarian shared with the viewers an options trading idea in SBA Communications Corporation (NASDAQ: SBAC). He noticed big call options volume in the name and he thinks it would be a good idea to get a long position.

nyse stocks: Cidara Therapeutics, Inc.(CDTX)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

nyse stocks: NOW Inc.(DNOW)

Advisors’ Opinion:

  • [By Matthew DiLallo, Tyler Crowe, and Jason Hall]

    Oil prices haven’t gotten off to the fast start many expected, falling around 6% on average during the first quarter of the year. That slump came despite OPEC’s best efforts since producing nations have achieved fairly good compliance on their planned output cuts. That said, despite the lackluster oil market, we still see some interestingopportunities in the oil market. Three stocks we really like right now are DistributionNOW(NYSE:DNOW),Phillips 66(NYSE:PSX), andConocoPhillips(NYSE:COP), which all should do well in the current oil market.

Top 10 Performing Stocks To Own Right Now

Right now, the whole market is doing well, tech is doing really well, and big tech is doing really, really well. Over the past year, the S&P 500 is up 20%. The NASDAQ-100 is up 33%. FANG stocks have rallied anywhere from 36% to 70%. But one stock outperforming all of them? Adobe Systems Incorporated (NASDAQ:ADBE). ADBE stock is up 75% over the past year and 200% over the past five years.

Source: Shutterstock

I think this name easily has another 15%-plus upside to well over $200.

Top 10 Performing Stocks To Own Right Now: Matador Resources Company(MTDR)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Our peer group is up an average of 46% over the past 4 weeks in response to a 30% rebound in the 12-month strip NYMEX oil price. Some of the largest gainers include Hold and Sell rated stocks that we would not chase such asDenbury Resources (Sell, +138%), Halcon Resources (HK) (Sell, +147%), Jones Energy (JONE) (Hold, +166%), Rex Energy (REXX) (Sell, +60%), Sanchez Energy (SN) (Hold, +93%), Ultra Petroleum (UPL) (Sell, +61%), andWhiting Petroleum (Hold, +103%), which have outperformed the E&P Index (+32%) over the same time period. Balance sheets and/or well level returns remain challenged for these companies despite improved oil prices. While we believe oil markets should re-balance over the next 12 to 15 months, the recent recovery to $40 could reverse during 2Q16 as bloated inventories continue to rise, new volumes from Iran pressure an oversupplied market, and a highly anticipated decline in non-OPEC supply (especially in the U.S.), is not as steep as expected. The risk of an oil price retracement, which would significantly pressure the recent out-performers, outweighs the upside in these stocks, in our view. However, we are raising our target prices on Buy ratedAnadarko Petroleum ($54 from $48), Concho Resources (CXO) ($120 from $109), Matador Resources (MTDR) ($22 from $21),Noble Energy (NBL) ($40 from $34), SM Energy (SM) ($22 from $15), Rice Energy ($14 from $12), Pioneer Natural Resources (PXD) ($155 from $135),Continental Resources ($32 from $28), and Parsley Energy (PE) ($24 from $23). We believe our Buy-rated stocks are better positioned to weather challenging oil markets.

  • [By Ezra Schwarzbaum]

    But despite positioning that would thrash other similar companies, Resolute fought through thanks to significant and efficient productivity in its Delaware Basin assets. Wangler believes the strengthening of previous concern areas will make the company a solid investment.

    Matador Resources Co (NYSE: MTDR), $32 Price Target

    Matador has grown its reserves throughout the commodity cycle, as well as its production and cash flow. Haas also likes the company’s history of identifying and acquiring acreage early and cheaply. Much of the analyst’s positive outlook is derived from Matador’s successful monetization of midstream assets and pattern of reinvestment.

Top 10 Performing Stocks To Own Right Now: Lithium Americas Corp. (LACDF)

Advisors’ Opinion:


    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].


    Still, reading between the lines, it’s been clear which names he has liked over the months and years. Lithium Americas (OTCQX:LACDF) and SQM (NYSE:SQM) are prime examples. Consider that LAC shares have more than doubled from an early July low of C$0.78 (it closed at C$1.70 on Sept. 15th) when rumblings suggested that SQM might not move forward on the LAC/SQM Cauchari-Olaroz project. Joe was among the first to squash those rumors, setting up what turned out to be a highly profitable buying opportunity. SQM is up 120% in the past 12 months (by comparison, the Global X Lithium ETF (LIT) is up 54%, and the S&P 500 Index is up 16%).

Top 10 Performing Stocks To Own Right Now: Sanofi(SNY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Hopes were high for MannKind (MNKD) when its inhaled insulin Afrezza was approved by the FDA more than two years ago. At the time, Barron’s warned that it was time to dump MannKind’s shares, something that now seems prescient, as its shares have since tumbled 95%. No wonder, as the news since then has been far from good. MannKind found a partner in Sanofi (SNY), only to get dumped in early 2016, and has since been forced to sell property to raise cash. And now MannKind could be on the verge of being delisted from the Nasdaq due to its sub $1 stock price. What now? Piper Jaffray’sJoshua Schimmer and team see a reverse stock split in MannKind’s future:

  • [By Stephen Mack]

    JNJ has recently made substantial investments in its pharmaceuticals pipeline. Most notably, in January the company beat Sanofi SA (NYSE: SNY) to buy a stake in Swiss drug company Actelion. The pairing is a perfect match, as it bulks up Johnson & Johnson’s pipeline, and gives Actelion the reach of a global powerhouse.

  • [By Money Morning Staff Reports]

    The drug is currently in phase 1 of an extensive trial, after which the U.S. Department of Health and Human Services (DHHS) will pass the vaccine on to French pharmaceutical company Sanofi SA (NYSE ADR: SNY). Sanofi will carry out the vaccine’s phase 2 and phase 3 trials because “of the high risk and high costs involved in advanced vaccine development,” the Army wrote in an April 21 public letter on its website.

  • [By Sean Williams]

    MannKind has just one Food and Drug Administration-approved therapy, an inhalable type 1 and type 2 diabetes drug known as Afrezza. On paper Afrezza looked like a winner. It was fast-acting, it metabolized through the body more quickly than traditional insulin, and it was exceptionally convenient since there were no needles involved. The company also wound up licensing the drug out to Sanofi (NYSE:SNY) in 2014, netting much needed upfront capital and help on the expenses front.

  • [By Emily Stewart]

    Paulson picked up 395,500 shares of Sanofi SA (SNY) valued at $16.6 million.

    Sanofi is a health care company engaged in the research, development, manufacture and marketing of healthcare products. It has a $101.4 billion market cap and trades at a P/E of 21.18. 

Top 10 Performing Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

Top 10 Performing Stocks To Own Right Now: Plug Power Inc.(PLUG)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap FuelCell Energy along withalternative energy or fuel cell stocks like Ballard Power Systems Inc (NASDAQ: BLDP), Hydrogenics Corporation (NASDAQ: HYGS) and Plug Power Inc (NASDAQ: PLUG) all peaking in 2014 with some signs of stabilization early last year before they drifted a bit lower:

  • [By Peter Graham]

    A long term performance chart shows Ballard Power Systemsalong with alternative energy or fuel cell stock peers like small capsFuelCell Energy Inc (NASDAQ: FCEL), Hydrogenics Corporation (NASDAQ: HYGS) and Plug Power Inc (NASDAQ: PLUG) all peaking in 2014 before falling back; but BLDP and PLUG have picked up steam earlier this year:

  • [By Peter Graham]

    Small cap fuel cell stock Plug Power Inc (NASDAQ: PLUG) reported Q1 2017 earnings before the market opened with the Company now using anew Shareholder Letter format to report earnings. GAAP revenue was $15.2 million versus $15.3 million in the first quarter of 2016. Q1 2017 revenue represents 30% year-over-year growth in recurring revenue streams which wasoffset by a reduction of system deployments year over year due to the timing of when planned 2017 deployments will be commissioned. The net loss was $24.1 million versus anet loss of $11.8 million. As of March 31, 2017, Plug Power had total cash of $65.7 million, including cash and cash equivalents of $11.8 million and restricted cash of $53.9 million.

  • [By Dan Caplinger]

    Still, some stocks managed to buck the negative sentiment on Tuesday, and Sears Holdings (NASDAQ:SHLD), Plug Power (NASDAQ:PLUG) and Coeur Mining (NYSE:CDE) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Sreekanth Anasa]

    In case of QCOM stock, the shorter term 50-day simple moving average (SMA) is all set to break above its long-term 200-day SMA, separated by just a few cents, which are also the most commonly used moving averages for ‘golden cross’. Investors should also note that this is the first time in almost 18 months this bullish crossover is set to occur. And, the last time Qualcomm stock made ‘golden cross’, it set out on a rally. However, a word of caution for investors, the current Relative Strength Index (RSI) reading of 76.17, which is well above the commonly used overbought threshold of 70, suggests that the stock is in overbought territory, hinting that the upside could be limited. Though the Bollinger Bands indicator is not flashing an overbought signal and generally the combination of these two indicators is considered as a strong signal.

    Is a bottom in sight for Plug Power Inc (NASDAQ:PLUG) stock?

    The sell-off inalternative energy technology company Plug Power Inc (NASDAQ:PLUG) doesn’t seem to stop after its Q3 earnings release last week. Plug Power stock dropped another 5.8% yesterday and has lost more than 25% of its value after the earnings announcement. The Latham, New York-based company delivered a non-GAAP earnings loss of 4 cents, which was in-line with the analyst estimates on revenue of $61.43 million, bettering the expectations by $5.64 million. The revised full-year adjusted gross margin falling below the company’s previous guidance of 8% to 12% also had not gone down well with the investors partially contributing to the sell-off. Now, if one take’s a look at the PLUG stock technical chart, they would be rather disappointed as the downtrend is likely to continue for some time now going by the technical set up.

  • [By Lisa Levin]

    Wednesday afternoon, the industrial sector proved to be a source of strength for the market. Leading the sector was strength from Plug Power Inc (NASDAQ: PLUG) and Envirostar Inc (NYSE: EVI).

Top 10 Performing Stocks To Own Right Now: Abbott Laboratories(ABT)

Advisors’ Opinion:

  • [By Matt Hogan]

    AbbVie has distributed a significant amount of its earnings in the form of dividends (~60 percent) since the company spun off from Abbott Laboratories (NYSE: ABT) in 2013. The company appears to be trading at a 10 percent discount to fair value when applying similar assumptions in the 5-year dividend discount model as shown below.

  • [By Sean Williams]

    Finally, and as the icing on the cake, Wall Street uncovered via a Securities and Exchange Commission filing that Abbott Laboratories (NYSE:ABT) sold 44 million shares of Mylan stock at $41.60, reducing its remaining position in the company to 25.75 million shares, or about 4.8% of its outstanding shares. Considering all the issues Mylan has had recently, the fact that Abbott substantially pared its large holding in the company is a bit worrisome.


    In the Lightning Round, Cramer was bullish on Abbott Laboratories (ABT) , Dycom Industries (DY) and Howard Hughes (HHC) .

    Cramer was bearish on Headwaters (HW) , EnergySolutions (ES) , Western Refining (WNR) and Horizon Pharmaceuticals (HZNP) .

Top 10 Performing Stocks To Own Right Now: Cidara Therapeutics, Inc.(CDTX)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

Top 10 Performing Stocks To Own Right Now: Madison Square Garden Inc.(MSG)

Advisors’ Opinion:

  • [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

    Meanwhile, Mark Boyar, of The Boyar Value Fund, recommends another household name: Madison Square Garden (MSG). He thinks the Dolan family could take the company private.

  • [By Monica Gerson]

    Madison Square Garden Co (NYSE: MSG) is estimated to report a quarterly loss at $0.34 per share on revenue of $325.53 million.

    Gogo Inc (NASDAQ: GOGO) is projected to report a quarterly loss at $0.42 per share on revenue of $137.58 million.

Top 10 Performing Stocks To Own Right Now: News Corporation(NWS)

Advisors’ Opinion:

  • [By Monica Gerson]

    News Corp (NASDAQ: NWS) reported a profit of $506 million, or $0.87 per share for the year ended June 30, versus a year-ago loss of $2.08 billion, or $3.58 per share. Its revenue rose 2.7% to $8.89 billion. However, analysts were expecting earnings of $0.57 per share on revenue of $8.96 billion. News Corp shares fell 1.28% to close at $16.91 on Friday.

Top 10 Performing Stocks To Own Right Now: Cross Timbers Royalty Trust(CRT)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Under the Radar Moversnewsletter suggested shorting small cap trust stock Cross Timbers Royalty Trust (NYSE: CRT):

    On the close-up detailed chart of Cross Timber Royalty we can see how well-developed the downtrend is, but what’s so eye-catching is the way the selling volume is starting to build on the way down. The recent bearish crosses of all the key moving average lines were indeed telling of trouble.